FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmacology, namely to drugs possessing neurotropic activity. Disclosed is the use of isorhamnetin 3-O-β-D-glucopyranoside as a drug having neurotropic activity for treating neuroses and psychosis.
EFFECT: using the invention enables treating neuroses and psychosis effectively.
7 cl, 1 dwg, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF SALICIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832938C1 |
USE OF CYNAROSIDE HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832839C1 |
USE OF APIGENIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2832841C1 |
USE OF OREGANOL A WITH NEUROTROPIC ACTIVITY | 2022 |
|
RU2802871C1 |
USE OF COSMOSIIN HAVING NEUROTROPIC ACTIVITY | 2023 |
|
RU2833214C1 |
USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
USE OF GAULTERIN AS ANTIDEPRESSANT | 2023 |
|
RU2825385C1 |
"FLUOGLYSINE" MEDICINAL PREPARATION FOR TREATING DIFFERENT FORMS OF DEPRESSION | 2002 |
|
RU2232574C2 |
METHOD OF OBTAINING OREGANOL A, HAVING NEPHROTROPIC AND NEUROTROPIC ACTIVITY | 2022 |
|
RU2804299C1 |
ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
Authors
Dates
2025-01-15—Published
2024-02-13—Filed